<DOC>
	<DOCNO>NCT01539031</DOCNO>
	<brief_summary>The purpose study compare 23 mg donepezil sustain release currently market formulation 10 mg donepezil immediate release patient severe Alzheimer 's disease .</brief_summary>
	<brief_title>Compare Efficacy Safety Donepezil Hydrochloride 23 mg Treatment With Continuation Donepezil Hydrochloride 10 mg Treatment Japanese Subjects With Severe Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria Diagnosis : diagnostic evidence probable Alzheimer 's disease ( AD ) consistent Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIVTR ) 290.00 290.10 Mini Mental State Examination ( MMSE ) less equal 12 great equal to1 inclusive , Screening SIB le equal 90 great equal to10 Screening Baseline No evidence focal disease account dementia cranial image ( magnetic resonance image [ MRI ] compute tomography [ CT ] ) . Subject age range : male female subject great equal 50 year age inclusive Outpatients ( patient nurse home eligible ) The subject must caregiver provide inform consent separately his/her participation study , regular contact subject . Stable donepezil dose 10 mg , take single , daily dose great equal 3 month prior Screening visit Subjects swallow hole tablet , tablet break crush Comorbid medical condition must clinically stable prior Screening unless otherwise specify . Written inform consent obtain subject ( possible ) subject 's legal guardian representative ( accord Japanese regulation appropriate ) prior begin screen activity . Exclusion Criteria Subjects know history disorder affect cognition ability ass cognition distinguishable AD Subjects dementia complicate organic disease AD delirium Known hypersensitivity donepezil piperidine derivative , excipients study drug formulation Patients expect live nursing home within 24 week randomization ( eligible temporary ) Use prohibit prior concomitant medication . Memantine allow take prescribed dos less equal 20 mg/day , provide dose stable least 6 month prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Delirium</keyword>
	<keyword>Amnestic</keyword>
	<keyword>Cognitive Disorders</keyword>
	<keyword>Donepezil</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Tauopathies</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Cholinesterase Inhibitors</keyword>
	<keyword>Enzy</keyword>
</DOC>